A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Stargardt Disease · Stargardt Macular Degeneration · Stargardt Macular Dystrophy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCHealth Sue Anschutz-Rodgers Eye Center,, Aurora, Colorado, United States
Principal InvestigatorBascom Palmer Eye Institute, Miami, Florida, United States
Principal InvestigatorMassachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Contact: Study coordinator (Center for Clinical Research)Principal InvestigatorOregon Health & Science University, Portland, Oregon, United States
Principal InvestigatorRetina Foundation of the Southwest, Dallas, Texas, United States
Principal Investigator